Post-Bariatric Hypoglycemia (PBH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report

Post-bariatric hypoglycemia (PBH) is when patients undergoing various bariatric procedures experience low blood glucose levels following meals. PBH is recognized as a metabolic complication associated with different types of bariatric surgery (BS). While BS is currently considered the most effective and relatively safe treatment for obesity and its related complications, the development of PBH can significantly impact patients\’ quality of life. PBH is characterized by postprandial hypoglycemic symptoms, typically occurring between one and four hours after a meal, with a higher frequency observed one-year post-surgery. These symptoms are accompanied by low blood glucose levels, often confirmed through provocative testing. The prevalence of PBH varies depending on the diagnostic tools employed. Recent studies have reported prevalence rates of up to 88% using a mixed meal tolerance test (MMTT) and up to 75% using continuous glucose monitoring (CGM). PBH can present with a range of autonomic symptoms, such as tremors, palpitations, and anxiety, as well as neuroglycopenic symptoms, including dizziness, confusion, and even loss of consciousness. However, a significant proportion of PBH patients remain asymptomatic, complicating the diagnosis of this condition. Although the long-term effects of asymptomatic PBH are currently unknown, individuals with symptomatic PBH are known to experience a reduced quality of life as assessed through questionnaires. The diagnosis of PBH is challenging for several reasons. Firstly, PBH, often referred to as \”late dumping syndrome,\” must be distinguished from \”early dumping syndrome,\” which typically occurs within the first 30 minutes after a meal and the first few months post-surgery. Early dumping syndrome is caused by the rapid passage of nutrients into the small intestine, where the bolus\’s hyperosmolarity triggers a fluid shift from the intravascular component to the intestinal lumen. This leads to gastrointestinal symptoms such as abdominal pain, bloating, increased bowel sounds, nausea, diarrhea, and vasomotor symptoms, including fatigue, flushing, palpitations, tachycardia, hypotension, and, rarely, syncope. The diagnosis of PBH is further complicated by the unique glycemic variability observed in patients who have undergone Roux-en-Y gastric bypass (RYGB) or sleeve gastrectomy (SG). This variability is characterized by earlier blood glucose peaks and lower nadirs, presenting a challenge for the biochemical diagnosis of PBH during standardized dynamic testing. Nutritional therapy is generally considered the cornerstone of PBH treatment. Nutritional therapy aims to prevent initial postprandial glycemic peaks by restricting carbohydrate intake, avoiding high glycemic index (GI) foods and simple sugars, increasing meal frequency, and reducing meal size. High GI foods provoke greater insulin peaks and pose a higher risk of PBH. Despite the empirical recommendation of low GI foods for treating PBH, these dietary modifications are essential for managing the condition effectively.

Thelansis’s “Post-Bariatric Hypoglycemia (PBH) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033\” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Post-Bariatric Hypoglycemia (PBH) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Post-Bariatric Hypoglycemia (PBH) across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Post-Bariatric Hypoglycemia (PBH) Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Read more: Post-Bariatric Hypoglycemia (PBH) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033